Research programme: CAR-T regulatory cell therapy - Quell Therapeutics/University of Sheffield
Latest Information Update: 28 Nov 2024
At a glance
- Originator Quell Therapeutics; University of Sheffield
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in United Kingdom (Parenteral)
- 26 Oct 2020 Quell Therapeutics enters into collaboration agreement with University of Sheffield for discovery and validation of CAR-Treg cell therapies in Neurodegenerative disorders
- 26 Oct 2020 Early research in Neurodegenerative disorders in United Kingdom (Parenteral)